Connect with us
European Gaming Congress 2024

Fintech PR

TCI Fund Management Establishes Strategic Presence in EMEA Region with Opening of Abu Dhabi Office

Published

on

tci-fund-management-establishes-strategic-presence-in-emea-region-with-opening-of-abu-dhabi-office

Sir Christopher Hohn to Present at Abu Dhabi Finance Week November 27-30

ABU DHABI, Nov. 23, 2023 /PRNewswire/ — TCI Fund Management Limited (“TCI”), a leading $60bn investment firm, today announced the opening of an Abu Dhabi office, establishing a strategic presence in the United Arab Emirates and EMEA. Bronwyn Owen, Global Head of Investor Relations and Director of TCI Fund Management (AD) Limited has relocated to Abu Dhabi from New York and will head up the new office.

The firm plans to leverage the Abu Dhabi office and in-person presence in building key regional relationships. A physical location in the region provides TCI access to valuable markets in terms of talent and capital as it continues to expand its capabilities and expertise. Further, the office provides TCI, a foothold in the region that can be leveraged to continue its efforts catalyzing climate action within the private finance sector.

“The Middle East is a vital market for the investment management industry, both from a talent and asset growth perspective, as well as a critical partner in global efforts to reduce carbon emissions and climate change,” said Sir Christopher Hohn, TCI Founder and Portfolio Manager. “We look forward to establishing our team there to reach a broader investor base and to expand my philanthropic activities. We are also excited to partner with the local community to help enhance opportunities for investment managers in the region and to further our ongoing efforts to reduce the impacts of the present climate crisis through pushing for climate action plans.”

H.E. Ahmed Jasim AL Zaabi, Chairman of ADGM said, “We are delighted to welcome TCI to ADGM. TCI’s new base underscores ADGM’s rise as an international financial hub and reinforces Abu Dhabi’s position as a prospering centre for the investment management industry and its leading role in the energy transition underpinned by the UAE’s strategic value to global finance and equally its unwavering commitment to climate action”.

Advertisement
Stake.com

In his personal capacity as Founder and Chair of the Children’s Investment Fund Foundation (CIFF), Sir Christopher also hopes that TCI’s presence in the region will enable him to raise the profile of the important work CIFF and other philanthropies are doing in the areas of climate action, health and nutrition, attracting much needed partnerships and co-funding from local organisations and individuals to tackle these global issues.  CIFF is an independently endowed charity which is regulated under UK law and is wholly separate from TCI.

As part of TCI’s office opening, Sir Christopher Hohn will be speaking at the Abu Dhabi Finance Week leadership roundtable “Investing in the Transition Era” on November 27th, and at R.A.C.E. Sustainability Summit on the subject of growing Climate Finance on November 30th.  Sir Christopher will headline the COP28 Business & Philanthropy Climate Forum on December 1st in a fireside chat on “Tackling Greenwashing and Greenhushing”.

TCI’s presence further solidifies the UAE’s growing importance in the investment management industry and aligns with recent trends as firms put boots on the ground in the Middle East. 

About TCI Fund Management Limited

Founded in 2003 by Sir Christopher Hohn, TCI is a leading $60bn investment firm headquartered in London with offices in New York and Abu Dhabi. TCI manages assets for institutional investors around the world including sovereign wealth funds, corporate and public pension plans, foundations, endowments and for some of the world’s leading family offices. Sir Chris is an activist investor and in recent years, has become an outspoken advocate of urgent action on the climate crisis, and a prolific contributor to the cause.

Advertisement
Stake.com

www.tcifund.com

About The Children’s Investment Fund Foundation UK (“CIFF”)

A registered charity in England and Wales, CIFF focuses on improving the lives of children living in poverty in developing countries and is the one of the largest children’s charities in the world. In 2019, Forbes put Hohn in the list of the world’s most generous philanthropists outside of the US. 

www.ciff.org

TCI’s Investments

Advertisement
Stake.com

Equities – TCI is a value orientated, fundamental investor which invests globally in strong businesses with sustainable competitive advantages. Using a private equity approach, TCI conducts deep fundamental research, constructively engages with management and adopts a long-term investment horizon. TCI is an opportunistic investor investing from time to time in corporate transformations and special situations. TCI will drive outcomes by using activism when appropriate. The TCI Master Fund is highly concentrated to maximize alpha.

Real Estate – TCI’s real estate lending business was established in 2014. The TCI Real Estate Partners Lending Funds invest alongside The Children’s Investment Fund Foundation (UK) (CIFF). These funds focus on first mortgage and senior secured lending on high quality assets in prime locations with a concentration on major cities in North America and Europe.

Contact Information

Bronwyn Owen, CFA
Global Head of Investor Relations
Managing Director, TCI Fund Management (AD) Limited
ADGM Square, Al Maryah Island
Al Maqam Tower, 34th Floor
Abu Dhabi, UAE
UAE: +971 55 820 1627
E: [email protected]

For Media
ASC Advisors
Steve Bruce / Taylor Ingraham
[email protected] / [email protected]
+1 203 992 1230

Advertisement
Stake.com

View original content:https://www.prnewswire.co.uk/news-releases/tci-fund-management-establishes-strategic-presence-in-emea-region-with-opening-of-abu-dhabi-office-301996478.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

Advertisement
Stake.com

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

Advertisement
Stake.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

Advertisement
Stake.com

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Advertisement
Stake.com

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

Advertisement
Stake.com

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Advertisement
Stake.com
Continue Reading

Trending